Metformin hydrochloride chewable tablet and preparation method thereof

Abstract

The invention belongs to the field of medical technology and relates to a metformin hydrochloride chewable tablet and a preparation method thereof. The metformin hydrochloride chewable tablet is used for patients suffering from type-2 diabetes with pure unsatisfied diet control, in particular used for patients suffering from obesity and hyperinsulinemia, not only has the effect of reducing blood sugar level but also reducing body weight and alleviating hyperinsulinemia. The metformin hydrochloride chewable tablet is effective for some patients who are treated by sulfonylurea with poor curative effects, and has better effects in combination with sulfonylurea and small intestine glycosidase inhibitors or thiazolidinedione hypoglycemic drugs compared with single use. The metformin hydrochloride chewable tablet can be also used for patients with insulin treatment so as to reduce insulin dosage. The metformin hydrochloride chewable tablet is good in taste, simple and convenient in preparation process and easy to operate, especially suitable for children patients and fills up the blank of medication of children suffering from diabetes.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a metformin hydrochloride chewable tablet and a preparation method thereof, which is used for type 2 diabetes patients who are not satisfied with simple diet control, especially obese and hyperinsulinemia patients. The medicine not only has hypoglycemic effect , may also have weight loss and hyperinsulinemic effects. It can be effective for some patients with poor curative effect of sulfonylureas, such as combined with sulfonylureas, intestinal glycosidase inhibitors or thiazolidinedione hypoglycemic drugs, the effect is better than that of single use. It can also be used in patients on insulin therapy to reduce insulin dosage. Background technique [0002] In 1957, metformin hydrochloride developed by Bristol-Myers Squibb was first approved as a hypoglycemic drug for clinical use in France. In 2004, the European Union approved the hypoglycemic drug metformin hydrochlori...

AI Technical Summary

Problems solved by technology

Although liquid preparations are more convenient to use than ordinary tablets and capsules currently on the market, one of the excipients used—sodium benzoate is a preservative. In recent years, studies have found that sodium benzoate can destroy an important part of human cell DNA, which is associated with many diseases. It is related to the incidence of the disease, and it is more harmful to children who are in the growth and development period. Some developed countries have banned the addition of sodium benzoate in pregnant women and children's products.

Images